

<b>Supplemental Table 2: Univariable and multivariable Cox PH regression for overall survival for all patients (N=612)</b>						
<b>Variable</b>	<b>Univariable</b>			<b>Multivariable</b>		
	<b>HR</b>	<b>95%CI</b>	<b>p</b>	<b>HR</b>	<b>95%CI</b>	<b>p</b>
Perioperative transfusion						
No (reference)						
Yes	1.0	.83, 1.20	.97	1.18	.94, 1.48	.15
Treatment arm						
Primary TRS + adjuvant chemotherapy (reference)						
Neoadjuvant chemotherapy + interval CRS	.99	.82, 1.20	.95	.99	.80, 1.23	.91
Residual Disease						
R0 (reference)						
R1	1.51	1.22, 1.86	<.001	1.52	1.19, 1.95	.001
WHO performance status						
0 (reference)						
1	1.28	1.05, 1.56	.02	1.21	.97, 1.52	.09
2	1.22	.90, 1.66	.19	.75	.52, 1.09	.13
Histologic subtype						
Serous (reference)						
Non-serous	1.24	1.02, 1.51	.03			
Grade						
Well to moderately differentiated (reference)						
Poorly differentiated	.90	.69, 1.16	.40			
Stage						
III (reference)						
IV	1.43	1.16, 1.78	.001	1.55	1.21, 1.98	<.001
Primary site						
Ovary (reference)						
Primary peritoneal	1.21	.84, 1.74	.31			
Fallopian tube	3.40	1.09, 10.60	.04			
Other	2.0	.28, 14.28	.49			
Age						
≤ 62 years (reference)						
> 62 years	1.22	1.02, 1.48	.03	1.22	.99, 1.49	.06
BMI						
Normal (reference)						
Overweight	1.02	.82, 1.27	.85			
Obese	1.14	.87, 1.48	.34			
Underweight	1.48	.89, 2.47	.13			
Country						
Belgium (reference)						
Norway	1.09	.78, 1.53	.62	1.06	.72, 1.57	.77
United Kingdom	1.50	1.07, 2.09	.02	1.71	1.18, 2.49	.00
Canada	.91	.66, 1.25	.55	.83	.58, 1.18	.31
The Netherlands	1.39	.99, 1.95	.06	1.29	.88, 1.89	.19
Spain	1.30	.91, 1.86	.15	1.20	.79, 1.83	.39
Italy	.81	.51, 1.31	.40	.71	.41, 1.22	.22
Others	1.57	1.14, 2.16	.01	1.33	.89, 1.98	.16
Operative time in hours	.98	.93, 1.04	.56			